Trial Profile
Safety and Efficacy of Saracatinib In Subjects With Lymphangioleiomyomatosis
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Saracatinib (Primary)
- Indications Lymphangioleiomyomatosis
- Focus Therapeutic Use
- Acronyms SLAM-2
- 28 Jul 2020 Status changed from recruiting to discontinued.
- 24 Jan 2018 Planned End Date changed from 1 Dec 2017 to 30 Jul 2020.
- 24 Jan 2018 Planned primary completion date changed from 1 Dec 2017 to 30 Jul 2019.